PL2203433T3 - 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy - Google Patents
5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycyInfo
- Publication number
- PL2203433T3 PL2203433T3 PL08832210T PL08832210T PL2203433T3 PL 2203433 T3 PL2203433 T3 PL 2203433T3 PL 08832210 T PL08832210 T PL 08832210T PL 08832210 T PL08832210 T PL 08832210T PL 2203433 T3 PL2203433 T3 PL 2203433T3
- Authority
- PL
- Poland
- Prior art keywords
- oxoethoxy
- thiazolidine
- dione
- methoxyphenyl
- benzyl
- Prior art date
Links
- YAUMOGALQJYOJQ-UHFFFAOYSA-N 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound COC1=CC=CC(C(=O)COC=2C=CC(CC3C(NC(=O)S3)=O)=CC=2)=C1 YAUMOGALQJYOJQ-UHFFFAOYSA-N 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97263907P | 2007-09-14 | 2007-09-14 | |
| EP08832210A EP2203433B1 (en) | 2007-09-14 | 2008-09-15 | 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes |
| PCT/US2008/010723 WO2009038681A1 (en) | 2007-09-14 | 2008-09-15 | Thiazolidinedione analogues for the treatment of hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2203433T3 true PL2203433T3 (pl) | 2013-04-30 |
Family
ID=40239575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08832210T PL2203433T3 (pl) | 2007-09-14 | 2008-09-15 | 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8067450B2 (pl) |
| EP (1) | EP2203433B1 (pl) |
| JP (1) | JP5371988B2 (pl) |
| KR (1) | KR101537830B1 (pl) |
| CN (1) | CN101848901B (pl) |
| AU (1) | AU2008301905B2 (pl) |
| BR (1) | BRPI0817096B8 (pl) |
| CA (1) | CA2699289C (pl) |
| ES (1) | ES2398313T3 (pl) |
| IL (1) | IL204440A (pl) |
| MX (1) | MX2010002820A (pl) |
| NZ (2) | NZ597381A (pl) |
| PL (1) | PL2203433T3 (pl) |
| RU (1) | RU2486179C2 (pl) |
| WO (1) | WO2009038681A1 (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2001469B1 (en) | 2006-03-16 | 2012-05-23 | Metabolic Solutions Development Company LLC | Thiazolidinedione analogues |
| EP2486926A1 (en) | 2006-03-16 | 2012-08-15 | Metabolic Solutions Development Company LLC | Thiazolidinedione Analogues |
| US8304441B2 (en) | 2007-09-14 | 2012-11-06 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues for the treatment of metabolic diseases |
| AU2008301905B2 (en) | 2007-09-14 | 2013-06-27 | Cirius Therapeutics, Inc. | Thiazolidinedione analogues for the treatment of hypertension |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| WO2010105048A1 (en) * | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
| CN102753170A (zh) * | 2009-12-15 | 2012-10-24 | 新陈代谢解决方案开发公司 | 治疗糖尿病及其它代谢性疾病的ppar节制的噻唑烷二酮和组合 |
| AU2010331926B2 (en) * | 2009-12-15 | 2014-03-27 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| WO2011084459A1 (en) * | 2009-12-15 | 2011-07-14 | Metabolic Solutions Development Company | Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases |
| US8912335B2 (en) * | 2009-12-15 | 2014-12-16 | Metabolic Solutions Development Company, Llc | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases |
| AU2014202074B2 (en) * | 2009-12-15 | 2016-01-07 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8937182B2 (en) | 2010-04-19 | 2015-01-20 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
| AU2011242844A1 (en) * | 2010-04-21 | 2012-11-01 | Metabolic Solutions Development Company, Llc | Thiazolidinedione analogues |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| CA2807815C (en) * | 2010-08-10 | 2018-10-02 | Metabolic Solutions Development Company, Llc | Novel synthesis for thiazolidinedione compounds |
| US8933240B2 (en) | 2010-08-10 | 2015-01-13 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
| WO2012109495A1 (en) * | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| WO2012149083A1 (en) * | 2011-04-28 | 2012-11-01 | Metabolic Solutions Development Company, Llc | Ppar-sparing thiazolidinediones for the treatment of kidney related diseases |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013068486A1 (en) | 2011-11-08 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of male infertility |
| AU2014236510A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| US9562012B2 (en) | 2013-07-22 | 2017-02-07 | Metabolic Solutions Development Company, Llc | PPAR-sparing compounds for the treatment of metabolic diseases |
| EP3666273A3 (en) | 2014-01-15 | 2020-10-28 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| US20210038566A1 (en) | 2018-02-08 | 2021-02-11 | Enyo Pharma | Use of modulators of neet proteins for the treatment of infection |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| GB202210503D0 (en) | 2022-07-18 | 2022-08-31 | Univ Court Univ Of Glasgow | Materials and methods for treatment of chronic myeloid leukemia (CML) |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
| US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
| WO1986002073A1 (fr) | 1984-10-03 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant |
| CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物，其制备方法和用途 |
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US5167228A (en) | 1987-06-26 | 1992-12-01 | Brigham And Women's Hospital | Assessment and modification of endogenous circadian phase and amplitude |
| US5356913A (en) | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| ATE202352T1 (de) | 1991-04-11 | 2001-07-15 | Upjohn Co | Thiazolidindionderivate, herstellung und anwendung |
| NO302471B1 (no) | 1991-12-26 | 1998-03-09 | Sankyo Co | Tiazolidinforbindelser og farmasöytisk preparat |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| IL113313A (en) * | 1994-04-11 | 1999-09-22 | Sankyo Co | Heterocyclic compounds and pharmaceutical compositions containing the same |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| US5798375A (en) | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
| CA2371391A1 (en) | 1999-04-29 | 2000-11-09 | City Of Hope | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| WO2001000579A1 (en) | 1999-06-30 | 2001-01-04 | Tularik Inc. | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| PL363738A1 (pl) | 2001-04-26 | 2004-11-29 | Leciva A.S. | Sposób wytwarzania pioglitazonu jako środka przeciwcukrzycowego |
| WO2003026586A2 (en) | 2001-09-28 | 2003-04-03 | Teva Pharmaceutical Industries Ltd. | Pioglitazone hydrochloride |
| ATE372336T1 (de) | 2002-07-16 | 2007-09-15 | Cadila Healthcare Ltd | Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen |
| JPWO2004082715A1 (ja) * | 2003-03-20 | 2006-06-22 | エーザイ株式会社 | 炎症性腸疾患治療剤としての併用医薬 |
| US7230016B2 (en) | 2003-05-13 | 2007-06-12 | Synthon Ip Inc. | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same |
| JP2005015477A (ja) * | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| WO2005021542A2 (en) | 2003-08-28 | 2005-03-10 | Ranbaxy Laboratories Limited | Process for the preparation of pioglitazone |
| AR047541A1 (es) | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| KR100823414B1 (ko) | 2004-09-28 | 2008-04-17 | 오츠카 세이야쿠 가부시키가이샤 | 카르보스티릴 화합물 |
| EP2486926A1 (en) | 2006-03-16 | 2012-08-15 | Metabolic Solutions Development Company LLC | Thiazolidinedione Analogues |
| EP2001469B1 (en) * | 2006-03-16 | 2012-05-23 | Metabolic Solutions Development Company LLC | Thiazolidinedione analogues |
| JP2009530293A (ja) | 2006-03-16 | 2009-08-27 | メタボリック ソリューションズ ディベロップメント カンパニー | チアゾリジンジオン類似体およびグルココルチコイドアゴニストの併用療法 |
| AU2008301905B2 (en) | 2007-09-14 | 2013-06-27 | Cirius Therapeutics, Inc. | Thiazolidinedione analogues for the treatment of hypertension |
| WO2010105048A1 (en) | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
-
2008
- 2008-09-15 AU AU2008301905A patent/AU2008301905B2/en active Active
- 2008-09-15 WO PCT/US2008/010723 patent/WO2009038681A1/en not_active Ceased
- 2008-09-15 CA CA2699289A patent/CA2699289C/en active Active
- 2008-09-15 EP EP08832210A patent/EP2203433B1/en active Active
- 2008-09-15 BR BRPI0817096A patent/BRPI0817096B8/pt active IP Right Grant
- 2008-09-15 MX MX2010002820A patent/MX2010002820A/es active IP Right Grant
- 2008-09-15 ES ES08832210T patent/ES2398313T3/es active Active
- 2008-09-15 NZ NZ597381A patent/NZ597381A/xx unknown
- 2008-09-15 NZ NZ583889A patent/NZ583889A/en unknown
- 2008-09-15 KR KR1020107008064A patent/KR101537830B1/ko active Active
- 2008-09-15 RU RU2010114727/04A patent/RU2486179C2/ru active
- 2008-09-15 CN CN2008801147383A patent/CN101848901B/zh active Active
- 2008-09-15 PL PL08832210T patent/PL2203433T3/pl unknown
- 2008-09-15 JP JP2010524882A patent/JP5371988B2/ja active Active
- 2008-09-15 US US12/677,541 patent/US8067450B2/en active Active
-
2010
- 2010-03-11 IL IL204440A patent/IL204440A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008301905B2 (en) | 2013-06-27 |
| MX2010002820A (es) | 2010-04-01 |
| WO2009038681A1 (en) | 2009-03-26 |
| CA2699289C (en) | 2016-01-19 |
| BRPI0817096B8 (pt) | 2021-05-25 |
| AU2008301905A1 (en) | 2009-03-26 |
| BRPI0817096B1 (pt) | 2020-11-10 |
| KR20100075915A (ko) | 2010-07-05 |
| EP2203433B1 (en) | 2012-10-31 |
| RU2010114727A (ru) | 2011-10-20 |
| BRPI0817096A2 (pt) | 2017-05-02 |
| IL204440A (en) | 2013-05-30 |
| HK1146484A1 (en) | 2011-06-10 |
| NZ583889A (en) | 2012-01-12 |
| JP5371988B2 (ja) | 2013-12-18 |
| KR101537830B1 (ko) | 2015-07-17 |
| US20100222399A1 (en) | 2010-09-02 |
| ES2398313T3 (es) | 2013-03-15 |
| US8067450B2 (en) | 2011-11-29 |
| JP2010539171A (ja) | 2010-12-16 |
| RU2486179C2 (ru) | 2013-06-27 |
| CN101848901B (zh) | 2012-11-21 |
| EP2203433A1 (en) | 2010-07-07 |
| CA2699289A1 (en) | 2009-03-26 |
| CN101848901A (zh) | 2010-09-29 |
| NZ597381A (en) | 2013-03-28 |
| BRPI0817096A8 (pt) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2203433T3 (pl) | 5-(4-(2-(3-metoksyfenylo)-2-oksoetoksy)benzylo)tiazolidyno-2,4-dion do stosowania w leczeniu cukrzycy | |
| HRP20180667T1 (hr) | Protutijelo agonista kloto-beta za uporabu u liječenju dijabetesa ili otpornosti na inzulin | |
| BRPI0814294A2 (pt) | Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas. | |
| GB2454555B (en) | Alkoxy compounds for disease treatment | |
| ZA201001901B (en) | 5-substituted 2-(alkoxymethyl)furans | |
| ATE516272T1 (de) | 1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one | |
| BRPI0922642A2 (pt) | "formas polimórficas de sal de cloridrato de 3-(1-{3[5-(1-metil-piperidin-4-ilmetóxi)-piridin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila e processos de fabricação do mesmo" | |
| IL205742A0 (en) | 4-(4-cyano-2-thioaryl) | |
| PT2947072T (pt) | 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas | |
| IL209018A0 (en) | Benzene sulfonamide thiazole and oxazole compounds | |
| IL236883A0 (en) | Intermediate compounds for the preparation of (1-(s))-n-(s-cyclohexyl-2-{(4)-2-(s-(fluoro-benzoyl)-thiazol-2-yl]pyrrolidine-1-yl}-2 -oxo-ethyl)-2-methylamino-propionamide | |
| LT3228320T (lt) | Insulino ir glp-1 agonisto derinys | |
| BRPI0817537A2 (pt) | 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona | |
| IL212186A0 (en) | Fungicidal heterocyclic compounds | |
| IL200956A (en) | 1– [2– (2,4 – dimethylphenylsulfonyl) –phenyl] piperazine for the treatment of pain | |
| SI2632921T1 (sl) | Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj | |
| IL200403A0 (en) | Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2- diphenylhexanamide | |
| EP2064202A4 (en) | NOVEL (5S) -5- [4- (5-CHLORO-PYRIDIN-2-YLOXY) -PIPERIDIN-1SULFONYLMETHYL] -5-METHYL-IMIDAZOLINE-2,4-DIONE CRYSTALLINE G FORM (1) AND THE INTERMEDIATES | |
| IL209197A0 (en) | 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists | |
| CL2007003002A1 (es) | Compuesto 3-[1-metil-1-(6-trifluorometil-piridin-3-il)-etilamino]-5-(3-trifluorometoxifenil)-1-(4-trifluorometil-fenil)-pirrolidin-2-ona; y uso para el tratamiento de un trastorno seleccionado de obesidad, esquizofrenia, abuso de sustancias o depende | |
| ZA201003031B (en) | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid-465 | |
| EP2017252A4 (en) | 4- (4-alkylcyclohexyl) benzaldehyde | |
| EP2203441A4 (en) | PROCESS FOR OPTICALLY ACTIVE SULFOXIDE COMPOUNDS | |
| BRPI0717461A2 (pt) | Modificações de cristais de -3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin- 4-il]-pirrol-2,5-diona | |
| BRPI0912342A2 (pt) | tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados |